Satellite symposium: Antibody-Drug Conjugate Therapies in Locally Advanced (la) and Metastatic Urothelial Carcinoma (mUC)

  • Home
  • Satellite symposium: Antibody-Drug Conjugate Therapies in Locally Advanced (la) and Metastatic Urothelial Carcinoma (mUC)

Satellite symposium: Leveraging Antibody Drug Conjugates in the care of Patients with Metastatic Urothelial Carcinoma; Potential for Immunotherapy Combination Treatment

6th Oct 2023, 18:30 – 20:00 CEST

Bladder cancer is the tenth most common cancer worldwide. Urothelial carcinoma is responsible for over 90% of bladder cancers in Europe. Close to 60% of those diagnosed with urothelial carcinoma will at one point or another be diagnosed with metastatic disease (mUC) which carries an abysmal prognosis of only 5.5%. Drug discoveries in the field of urothelial carcinomas have exploded in the last decade which has led to the breakthrough development of immune checkpoint inhibitors (ICIs). Programmed cell death-1 (PD-1)/ programmed cell death-ligand 1 (PD-L1) inhibitors have shown increased clinical treatment. Still, many mUC patients still relapse following both platinum-based and immunotherapy-based regimens. This large clinical need for mUC patients, has led to the recent development and use of antibody-drug conjugates (ADCs). ADCs are small monoclonal antibodies that are connected to an anti cancer cytotoxic molecule. This allows the monoclonal antibody portion of the ADC to selectively deliver an anti cancer agent to a tumour cell that expresses a specific antigen. ADCs allow for conventional cytotoxic therapies to be renovated into highly effective and specific chemotherapies, potentially enabling synergistic outcomes when combined with immunotherapies. The European Society for Translational Medicine (EUSTM) has identified knowledge gaps in the understanding of ADC clinical trials, combination with immunotherapy and safety and efficacy profiles. This proposed 90-minute virtual satellite symposium will be held at the EUSTM-2023 Congress. The objective of this event is to increase the knowledge and understanding that HCPs have about the antibody drug conjugates (ADC) in treatment of mUC, the important and trail-blazing ADC clinical trials for mUC patients, and their respective safety and efficacy profiles.

Learning Objectives

After completing the independent medical educational activity, learners will be able to:

  • Describe clinical trials (both complete and ongoing) on the application of ADCs in the treatment of mUC patients.
  • Explain the rationale of ADC use in mUC alone and in combination with immunotherapeutics.
  • Recount emerging efficacy and safety data of ADCs in the treatment of mUC patients. 
Expert Talk 1: Review of Sacituzumab Govitecan Data in Urothelial Cancer

Prof. Yousef Zakharia
*University of Iowa, Genitourinary Oncology Program, Iowa City, United States, USA

Expert Talk 2: Current evidence and future prospects of Enfortumab Vedotin in Urothelial Cancer

Dr Shilpa Gupta
*Department of Solid Tumor Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA

Expert Talk 3: Emerging ADC Approaches in Urothelial Carcinoma

Dr Arnab Basu

O’Neal Comprehensive Cancer Center, The University of Alabama at Birmingham, Birmingham, AL, United States.


Epert Panel Discussion and Questions & Answers

Panelists: Prof. Yousef Zakharia, Dr Shilpa Gupta and Dr Arnab Basu.

Certificate of attendance: The certificates will be given to those attendees who will complete pre & post symposium evaluation quiz.

Conflict of interests: No known conflict of interests

Acknowledgment: This symposium is supported by educational grants from Astellas pharma.